FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Gano Kyle 2. Date of Event Requiring Statement (Month/Day/Year) 01/16/2013 3. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX] (Last) (First) (Middle) NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Business Dev Officer 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) SAN DIEGO, CA 92130 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 22,488 D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	  (1)	09/26/2013	Common Stock	2,400	$ 10.9	D	Â
Employee Stock Option (right to buy)	  (2)	03/12/2015	Common Stock	9,000	$ 5	D	Â
Employee Stock Option (right to buy)	  (3)	05/11/2017	Common stock	40,000	$ 2.59	D	Â
Employee Stock Option (right to buy)	  (4)	08/25/2021	Common Stock	75,000	$ 5.76	D	Â
Employee Stock Option (right to buy)	  (5)	01/12/2022	Common Stock	70,000	$ 8.66	D	Â
Employee Stock Option (right to buy)	  (6)	01/10/2023	Common Stock	60,000	$ 8.65	D	Â
Restricted Stock Unit	  (7)	  (7)	Common Stock	10,000	$ 0 (8)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Gano Kyle NEUROCRINE BIOSCIENCES, INC. 12780 EL CAMINO REAL SAN DIEGO, CA 92130	Â	Â	  Chief Business Dev Officer	Â

Signatures

Margaret E. Valeur- Jensen, By Power of Attorney		01/28/2013
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The option vested in annual installments over three years. The first installment became exercisable on September 26, 2007.
(2)	The option vested in annual installments over three years. The first installment became exercisable on March 12, 2009.
(3)	The option vests in monthly installments over three years. The first installment became exercisable on June 11, 2010.
(4)	The option vests in monthly installments over three years. The first installment became exercisable on September 25, 2011.
(5)	The option vests in monthly installments over four years. The first installment became exercisable on February 12, 2012.
(6)	The option vests in monthly installments over four years. The first installment becomes exercisable on February 10, 2013.
(7)	The restricted stock units will vest annually at 1/4 of the units vesting on January 10, 2014, January 10, 2015, January 10, 2016 and January 10, 2017, respectively.
(8)	Each restricted stock unit represents a contingent right to receive one share of Neurocrine Biosciences, Inc. Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.